Sorrento Therapeutics, Inc., a biopharmaceutical company, appointed Miranda Toledano as EVP of corporate development of Sorrento and president of LA Cell, Sorrento's joint venture with City of Hope.Staff Writer | San Diego, Ca., USA | Thursday September 15, 2016 4:33AM ET
Sorrento names Miranda Toledano as EVP, corporate development
Ms. Toledano joins Sorrento with 18 years of principal investment, financing and strategic advisory experience in the biopharmaceutical sector.
Since 2012, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co., now an FBR company, where she completed over 110 IPO and follow on equity offerings totaling over $4 billion in aggregate value.
Prior to joining MLV, she served in the investment group of Royalty Pharma where she focused on acquiring best in class biologic therapeutics targeting oncology, auto-immune and neurodegenerative indications.
From 1998 to 2003, she served as a Senior Manager at Ernst & Young (Israel) where she established the Life Sciences Corporate Finance group.
Ms. Toledano received a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.